Skip to main content
. 2019 Mar 4;68(6):871–882. doi: 10.1007/s00262-019-02317-9

Table 1.

Baseline characteristics of the patients

Prospective cohort (n = 29) Validation cohort 1
Bv+/− CT (n = 61)
Validation
cohort 2
CT only (n = 27)
Age (years)
 Median 59.1 56.9 59.9
 Range (32–76) (31–79) (37–81)
Use of glucocorticoids [n (%)]
 No 13 (45%) 18 (30%) 13 (48%)
 Yes 16 (55%) 43 (70%) 14 (52%)
Median survival (months)
 OS 8.5 8.0 9.0

Bv bevacizumab, CT chemotherapy, PFS progression-free survival, OS overall survival